The hematology diagnostic market is estimated to be valued at US$ 780.0 million in 2023 and is rising to US$ 2.0 billion by 2033. The market is estimated to register a CAGR of 9.9% during the forecast period. Various factors influencing the market include:
| Attributes | Details |
|---|---|
| Market CAGR (2023 to 2033) | 9.9% |
| Market Valuation (2023) | US$ 780 million |
| Market Valuation (2033) | US$ 2.0 billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The rising costs of hematology diagnostic and novel diagnostic procedures are limiting the market growth as people in low and middle-income countries find it difficult to receive expensive treatment, whereas lack of awareness may also restrict the market growth.
The rapidly growing blood diseases, related disorders, and infections such as blood clots, anemia, cancer, and hemophilia are driving market expansion. A report published by Bristol-Myers Squibb stated that nearly one million cases of blood cancer were recorded globally in 2020. Additionally, rising hemoglobinopathies disorder may increase the market growth during the forecast period.
The adoption of automation in hematology diagnostics to improve efficiency and standardize processes are rising market opportunity. Various diagnostic laboratories accept automation processes to collect samples, avail quick results, and recognition tests, and reduce administrative errors. These factors are estimated to increase the demand for automated hematology diagnostics during the forecast period.
Principal Consultant
According to Future Market Insights, the global hematology diagnostics market is projected at a healthy CAGR of 9.9% during the forecast period. Historically, the market registered a CAGR of 11.8% between 2017 and 2022.
The market changes as per the product adoption rates and device regulations under the macro and industrial dynamics. The key developments in the market include complete lab automation for hematology diagnostics. With the fourth wave of technology and automation around the globe, the market has been positively influenced by total laboratory automation strategies.
The market is estimated to reach US$ 2.0 billion during the forecast period. In the historical period, the market stood at a valuation of US$ 700 million from 2017 to 2022.
Hematology Diagnostics Market:
| Attributes | Hematology Diagnostics Market |
|---|---|
| CAGR (2023 to 2033) | 9.9% |
| Value (2023) | US$ 780 million |
| Value (2033) | US$ 2.0 billion |
| Trends | Increasing chronic, blood disorders, acute, and infectious diseases |
| Opportunities | Growing awareness, improved efficiency, standardized diagnostics, and government initiatives |
Molecular Diagnostics Market:
| Attributes | Molecular Diagnostics Market |
|---|---|
| CAGR (2023 to 2033) | 9.8% |
| Value (2023) | US$ 12.18 billion |
| Value (2033) | US$ 31.02 billion |
| Trends | Rising demand for (Polymerase chain reaction) PCR-based techniques and monitoring response |
| Opportunities | The stringent regulations, rising awareness, and innovative techniques |
Clinical Diagnostics Market:
| Attributes | Clinical Diagnostics Market |
|---|---|
| CAGR (2023 to 2033) | 7% |
| Value (2023) | US$ 80.27 billion |
| Value (2033) | US$ 157.90 billion |
| Trends | Rising bacteria, fungal and viral diseases increase the adoption of clinical diagnostics |
| Opportunities | Increasing product approval, research & development activities, and adoption of point-of-care clinical diagnostics |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Segments | Kit Type |
|---|---|
| Top Category | Blood Typing Kits |
| Historic CAGR | 11.2% |
| Forecast CAGR | 9.4% |
| Segments | Modality |
|---|---|
| Top Category | Lab-based Testing |
| Historic CAGR | 11% |
| Forecast CAGR | 9.1% |
The hospital segment holds a dominant market share and is predicted to maintain this stance during the forecast period. However, the diagnostic laboratories segment is expected to experience rapid growth over the forecast period owing to an increase in diagnostic centers. The increasing availability of advanced diagnostic instruments and devices and the demand for hospitals propel market growth.
Based on kit type, blood typing kits lead the global market by securing a CAGR of 9.4% during the forecast period. The rising demand for blood typing kits to perform blood tests easier and quicker and identify blood types. This segment contributes a huge revenue in the general healthcare routine and in discovering diseases which may drive market expansion.
The blood typing kits check various tests such as iron deficiency, allergy, vitamins, and anemia propel market opportunities. Historically, the blood typing kits captured a CAGR of 11.2% between 2017 and 2022.
| Country | United States |
|---|---|
| AGR (2017 to 2022) | 11.5% |
| AGR (2023 to 2023) | 9.7% |
| Valuation (2023 to 2033) | US$ 708.6 million |
| Country | United Kingdom |
|---|---|
| AGR (2017 to 2022) | 10.5% |
| AGR (2023 to 2023) | 8.9% |
| Valuation (2023 to 2033) | US$ 84.2 million |
| Country | China |
|---|---|
| AGR (2017 to 2022) | 11.1% |
| AGR (2023 to 2023) | 9.3% |
| Valuation (2023 to 2033) | US$ 143.5 million |
| Country | Japan |
|---|---|
| AGR (2017 to 2022) | 10.0% |
| AGR (2023 to 2023) | 8.4% |
| Valuation (2023 to 2033) | US$ 117.3 million |
| Country | South Korea |
|---|---|
| AGR (2017 to 2022) | 8.6% |
| AGR (2023 to 2023) | 7.6% |
| Valuation (2023 to 2033) | US$ 69 million |
Rising Incidence of Blood Cancer to Boost Hematology Diagnostics Demand!
The USA is securing a CAGR of 9.7% with a valuation of US$ 708.6 million during the forecast period. The USA has seen a spike in the incidence of blood cancer in recent years, and it is expected to increase in the coming years. Due to high technological proliferation, the USA hematology diagnostics market is expected to provide lucrative opportunities.
The presence of developed healthcare infrastructure and high research and development activity is predicted to flourish the USA market during the forecast period. Historically, the USA market captured a CAGR of 11.5% between 2017 and 2022.
South Korea registers a CAGR of 7.6% with a valuation of US$ 69 million during the forecast period. Focus on healthcare has bolstered in recent years in South Korea, creating many opportunities for healthcare diagnostic providers. The nation is also experiencing a surge in blood disorders and incidences of blood cancer. These factors are propelling the South Korean market during the forecast period. Historically, the market secured a CAGR of 8.6% between 2017 and 2022.
The United Kingdom's hematology diagnostics market is anticipated to hold a CAGR of 8.9%, with a valuation of US$ 84.2 million during the forecast period. The rising prevalence of blood cancer and the presence of key hematology diagnostics companies are expected to be key factors propelling the market growth.
The rising research & development and government initiatives to boost awareness for hematology diagnostics are driving the United Kingdom market. The increasing prevalence of blood disorders, healthcare, and rising instances of genetic blood disorders are expected to propel the United Kingdom market.
Rising investments in healthcare infrastructure and new market entrance are anticipated to promote the market potential in this region. Historically, the United Kingdom market secured a CAGR of 10.5% between 2017 and 2022.
The China hematology diagnostics market is anticipated to hold a CAGR of 9.3% with a valuation of US$ 143.5 million during the forecast period. Increasing healthcare infrastructure, urbanization, and improvement in diagnostic therapy products are driving the China market.
Rising government regulations and increasing initiatives to generate awareness are anticipated to boost market growth during the forecast period. Historically, China secured a CAGR of 11.1% between 2017 and 2022.
Hematology diagnostic providers are investing in the research & development of novel diagnostic solutions to enhance their market presence and boost revenue. Hematology diagnostic companies also focus on establishing new centers to deploy novel diagnostic solutions.
Healthcare manufacturers are developing various automation devices to reduce the workload and provide efficient results. Key players are conducting extensive research on the market and carrying out several marketing strategies to upsurge the market. Moreover, market players are involved in innovating new products and expanding distribution networks in the coming years.
Recent Development in the Market
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data | 2017 to 2022 |
| Market Analysis | US$ billion for Value |
| Key Countries Covered | United States, Canada, Germany, United Kingdom, France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Northern Africa, and South Africa, Türkiye |
| Key Segments Covered | Kit Type, Modality, Distribution Channel, Region |
| Key Companies Profiled | Meyland Smith A/S; Abbot Laboratories; Bio-Rad Laboratories; Sysmex Corporation; Mindray Medical International Limited; Siemens Healthlineers; F. Hoffman-La Roche Ltd.; HORIBA Ltd.; HemoCue AB; Danaher (Beckman Coulter Inc.); Nihon Kohden Corporation; EKF Diagnostics; Ortho Clinical Diagnostics; Drew Scientific |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, Drivers, Restraints, Opportunities and Threats Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The global hematology diagnostics market might create a revenue of around US$ 780 million in 2023.
In the United States the net worth of the total hematology diagnostics adopted by 2033 could be US$ 708.6 million.
China is the leading market and the regional demand is expected to grow at 9.3% CAGR until 2033.
The blood typing kits segment dominated and is forecasted to register 9.4% CAGR through 2033.
Between 2017 and 2022, the global demand for hematology diagnostics services surged at 11.8%.
1. Executive Summary | Hematology Diagnostics Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Producers 3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyers 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ million) & Volume (Units) Analysis, 2017 to 2022 4.2. Current and Future Market Size Value (US$ million) & Volume (Units) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Kit Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Kit Type, 2017 to 2022 5.3. Current and Future Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Kit Type, 2023 to 2033 5.3.1. Anemia and Iron Test Kits 5.3.2. Folic Acid Testing Kits 5.3.3. Sickle Cell Screening Kits 5.3.4. PT/INR Testing Kits 5.3.5. D-dimer Testing Kits 5.3.6. Blood Typing Kits 5.3.7. Leukemia Testing Kits 5.3.8. Sepsis Testing Kits 5.3.9. Antibiotic Resistance Panels 5.3.10. Bacterial & Fungal Panels 5.4. Y-o-Y Growth Trend Analysis By Kit Type, 2017 to 2022 5.5. Absolute $ Opportunity Analysis By Kit Type, 2023 to 2033 6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Modality 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Modality, 2017 to 2022 6.3. Current and Future Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Modality, 2023 to 2033 6.3.1. Point of Care 6.3.2. Lab-based Testing 6.4. Y-o-Y Growth Trend Analysis By Modality, 2017 to 2022 6.5. Absolute $ Opportunity Analysis By Modality, 2023 to 2033 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Distribution Channel, 2017 to 2022 7.3. Current and Future Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Distribution Channel, 2023 to 2033 7.3.1. Hospitals 7.3.2. Diagnostic Laboratories 7.3.3. Cancer Research Institutes 7.3.4. Retail Pharmacies 7.3.5. Drug Store 7.3.6. Online Sales Channels 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Region, 2017 to 2022 8.3. Current Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. East Asia 8.3.5. South Asia & Pacific 8.3.6. Middle East and Africa (MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022 9.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. United States of America 9.2.1.2. Canada 9.2.2. By Kit Type 9.2.3. By Modality 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Kit Type 9.3.3. By Modality 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022 10.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Kit Type 10.2.3. By Modality 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Kit Type 10.3.3. By Modality 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022 11.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom 11.2.1.3. Spain 11.2.1.4. France 11.2.1.5. Italy 11.2.1.6. Rest Of Europe 11.2.2. By Kit Type 11.2.3. By Modality 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Kit Type 11.3.3. By Modality 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022 12.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Kit Type 12.2.3. By Modality 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Kit Type 12.3.3. By Modality 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. South Asia & Pacific Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022 13.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Malaysia 13.2.1.2. Singapore 13.2.1.3. Philipinnes 13.2.1.4. Indonesia 13.2.1.5. Australia 13.2.1.6. New Zealand 13.2.1.7. Rest of South Asia & Pacific 13.2.2. By Kit Type 13.2.3. By Modality 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Kit Type 13.3.3. By Modality 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022 14.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. Turkey 14.2.1.3. South Africa 14.2.1.4. Rest of MEA 14.2.2. By Kit Type 14.2.3. By Modality 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Kit Type 14.3.3. By Modality 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. United States of America 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Kit Type 15.1.2.2. By Modality 15.1.2.3. By Distribution Channel 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Kit Type 15.2.2.2. By Modality 15.2.2.3. By Distribution Channel 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Kit Type 15.3.2.2. By Modality 15.3.2.3. By Distribution Channel 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Kit Type 15.4.2.2. By Modality 15.4.2.3. By Distribution Channel 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Kit Type 15.5.2.2. By Modality 15.5.2.3. By Distribution Channel 15.6. United Kingdom 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Kit Type 15.6.2.2. By Modality 15.6.2.3. By Distribution Channel 15.7. Spain 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Kit Type 15.7.2.2. By Modality 15.7.2.3. By Distribution Channel 15.8. France 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Kit Type 15.8.2.2. By Modality 15.8.2.3. By Distribution Channel 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Kit Type 15.9.2.2. By Modality 15.9.2.3. By Distribution Channel 15.10. China 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Kit Type 15.10.2.2. By Modality 15.10.2.3. By Distribution Channel 15.11. Japan 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Kit Type 15.11.2.2. By Modality 15.11.2.3. By Distribution Channel 15.12. South Korea 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Kit Type 15.12.2.2. By Modality 15.12.2.3. By Distribution Channel 15.13. Malaysia 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Kit Type 15.13.2.2. By Modality 15.13.2.3. By Distribution Channel 15.14. Singapore 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Kit Type 15.14.2.2. By Modality 15.14.2.3. By Distribution Channel 15.15. Philipinnes 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Kit Type 15.15.2.2. By Modality 15.15.2.3. By Distribution Channel 15.16. Indonesia 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Kit Type 15.16.2.2. By Modality 15.16.2.3. By Distribution Channel 15.17. Australia 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Kit Type 15.17.2.2. By Modality 15.17.2.3. By Distribution Channel 15.18. New Zealand 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Kit Type 15.18.2.2. By Modality 15.18.2.3. By Distribution Channel 15.19. GCC Countries 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Kit Type 15.19.2.2. By Modality 15.19.2.3. By Distribution Channel 15.20. Turkey 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Kit Type 15.20.2.2. By Modality 15.20.2.3. By Distribution Channel 15.21. South Africa 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Kit Type 15.21.2.2. By Modality 15.21.2.3. By Distribution Channel 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Kit Type 16.3.3. By Modality 16.3.4. By Distribution Channel 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Meyland Smith A/S 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.1.5.2. Product Strategy 17.1.1.5.3. Channel Strategy 17.1.2. Abbot Laboratories 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.2.5.2. Product Strategy 17.1.2.5.3. Channel Strategy 17.1.3. Bio-Rad Laboratories 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.3.5.2. Product Strategy 17.1.3.5.3. Channel Strategy 17.1.4. Sysmex Corporation 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.4.5.2. Product Strategy 17.1.4.5.3. Channel Strategy 17.1.5. Mindray Medical International Limited 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.5.5.2. Product Strategy 17.1.5.5.3. Channel Strategy 17.1.6. Siemens Healthlineers 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.6.5.2. Product Strategy 17.1.6.5.3. Channel Strategy 17.1.7. F. Hoffman-La Roche Ltd. 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.7.5.2. Product Strategy 17.1.7.5.3. Channel Strategy 17.1.8. HORIBA Ltd. 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.8.5.2. Product Strategy 17.1.8.5.3. Channel Strategy 17.1.9. HemoCue AB 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.9.5.2. Product Strategy 17.1.9.5.3. Channel Strategy 17.1.10. Danaher (Beckman Coulter Inc.) 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.10.5.2. Product Strategy 17.1.10.5.3. Channel Strategy 17.1.11. Nihon Kohden Corporation 17.1.11.1. Overview 17.1.11.2. Product Portfolio 17.1.11.3. Profitability by Market Segments 17.1.11.4. Sales Footprint 17.1.11.5. Strategy Overview 17.1.11.5.1. Marketing Strategy 17.1.11.5.2. Product Strategy 17.1.11.5.3. Channel Strategy 17.1.12. EKF Diagnostics 17.1.12.1. Overview 17.1.12.2. Product Portfolio 17.1.12.3. Profitability by Market Segments 17.1.12.4. Sales Footprint 17.1.12.5. Strategy Overview 17.1.12.5.1. Marketing Strategy 17.1.12.5.2. Product Strategy 17.1.12.5.3. Channel Strategy 17.1.13. Ortho Clinical Diagnostics 17.1.13.1. Overview 17.1.13.2. Product Portfolio 17.1.13.3. Profitability by Market Segments 17.1.13.4. Sales Footprint 17.1.13.5. Strategy Overview 17.1.13.5.1. Marketing Strategy 17.1.13.5.2. Product Strategy 17.1.13.5.3. Channel Strategy 17.1.14. Drew Scientific 17.1.14.1. Overview 17.1.14.2. Product Portfolio 17.1.14.3. Profitability by Market Segments 17.1.14.4. Sales Footprint 17.1.14.5. Strategy Overview 17.1.14.5.1. Marketing Strategy 17.1.14.5.2. Product Strategy 17.1.14.5.3. Channel Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Consumer Product
September 2021
REP-GB-7920
January 2023
300 pages
Explore Healthcare Insights
View Reports
Hematology Diagnostics Market
